LDLR and familial hypercholesterolemia: Further, evolocumab has been shown to significantly reduce LDL cholesterol and apoB in patients with homozygous familial hypercholesterolemia with either one or two defective LDLR alleles or one defective and one null LDLR allele, although this effect was not seen in patients with homozygous null mutations (15).